Every Form 4 that 908 Devices Inc. (MASS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MASS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MASS filings page.
908 Devices Inc. (MASS) director Christopher D. Brown reported selling 30,000 shares of common stock on September 2, 2026, at a weighted average price of $10.58 per share in open-market or private transactions. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025, and Brown now holds 775,559 shares directly.
908 Devices Inc. (MASS) reported that Chief Financial Officer Joseph H. Griffith IV sold 11,459 shares of common stock on August 25, 2026 in an open-market or private transaction. The weighted-average sale price was approximately $10.95 per share, with execution prices ranging from $10.65 to $11.03. Following this sale, Griffith directly holds 121,497 shares of 908 Devices Inc. common stock. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
908 Devices Inc. (MASS) reports that AWM Investment Company, Inc., a ten percent owner, indirectly sold 50,000 shares of common stock in open-market transactions on August 20–21, 2026. The sales, executed through limited partnerships advised by AWM, occurred at weighted average prices of about $10.52–$10.61 per share.
AWM is investment adviser to several Special Situations funds and has sole voting and investment power over large share blocks they hold. AWM disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.
908 Devices Inc. insider Kevin J. Knopp, President and CEO, reported selling a total of 27,622 shares of common stock in August 2026 under a Rule 10b5-1 trading plan adopted on May 20, 2025. Sales included 7,622 shares on August 13 at a weighted average $10.06 per share (actual prices ranged from $10.05 to $10.12) and 20,000 shares on August 17 at a weighted average $10.35 per share (range $10.08 to $10.45). Separately, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which the trustee, Knopp’s brother-in-law, has sole voting and dispositive control; Knopp may be deemed the beneficial owner.
908 Devices Inc. director Christopher D. Brown reported two open-market sales of common stock. On August 10, 2026, he sold 9,442 shares at a weighted average price of $9.03 per share, in multiple trades between $9.00 and $9.08. On August 11, 2026, he sold 8,358 shares at a weighted average price of $9.23, in trades between $9.06 and $9.36. The transactions, totaling 17,800 shares, were made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.
908 Devices Inc. President and CEO Kevin J. Knopp reported open-market sales of an aggregate 149,013 shares of common stock over August 10–12, 2026, at weighted average prices around $9.06–$10.16, in transactions made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. An additional 541,223 shares are reported as indirectly owned through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed the beneficial owner.
908 Devices Inc. director Christopher D. Brown reported selling 20,000 shares of common stock on August 5, 2026 at a weighted average price of $8.49 per share, with trade prices ranging from $8.35 to $8.595. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025 and left Brown with 823,359 shares of common stock held directly.
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc., reported an indirect sale of 50,000 shares of Common Stock on August 4, 2026 at a weighted average price of $8.3553 per share. The shares are held through limited partnerships advised by AWM, which reported aggregate post-transaction holdings of 4,829,773 shares and disclaimed beneficial ownership except to the extent of its pecuniary interest.
908 Devices Inc. director Brandi C. Vann exercised Restricted Stock Units into 5,192 shares of Common Stock on August 1, 2026. Each RSU represents a contingent right to one share and vests in substantially equal annual installments over three years following August 1, 2025. After this transaction, Vann reported holdings of 10,385 RSUs and 5,192 shares of Common Stock, all held directly.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 222 shares of common stock at a weighted average price of $9.07 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
After this sale, Knopp directly holds 732,603 shares of common stock. Separately, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed a beneficial owner.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of common stock. On July 2, 2026, he sold 2,200 shares at a weighted average price of $9.02 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he directly holds 843,359 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 20,000 shares of common stock at a weighted average price of $8.84 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
Following this sale, Brown directly holds 845,559 shares of 908 Devices common stock. Because the sale was carried out pursuant to a Rule 10b5-1 plan, the timing reflects a preset trading arrangement rather than a discretionary decision based on recent company developments.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 2,798 shares of common stock at a weighted average price of $9.09 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
Following the sale, Knopp directly holds 732,825 shares of common stock. In addition, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law serves as trustee and has sole voting and dispositive control; Knopp may be deemed the beneficial owner of those securities.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 9,900 shares of common stock at a weighted average price of $9.04 per share. The trades were executed at prices ranging from $9.00 to $9.08.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After the sale, Brown directly holds 865,559 shares of 908 Devices common stock, indicating he retains a substantial equity position in the company.
908 Devices Inc. President and CEO Kevin J. Knopp reported open‑market sales of 60,345 shares of common stock over three days at prices around $9.06–$9.14 per share. These transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on May 20, 2025, indicating they were pre‑scheduled.
After these sales, Knopp directly holds 735,623 shares of 908 Devices common stock. In addition, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother‑in‑law serves as trustee with sole voting and dispositive power, and of which Knopp may be deemed the beneficial owner.
908 Devices Inc. director Michele M. Leonhart exercised restricted stock units into common shares as part of equity compensation. She acquired 6,486 shares of common stock through the conversion of 6,486 restricted stock units at a stated price of $0.00 per share.
Following the transaction, Leonhart directly holds 27,054 shares of common stock. The restricted stock units underlying this exercise vest in substantially equal annual installments over three years starting June 25, 2024, with prorated vesting if service ends earlier, and represent the right to receive one share of common stock per unit when vested.
AWM Investment Company, Inc., a greater-than-10% owner of 908 Devices Inc., reported open-market sales of the company’s common stock through limited partnerships it advises. On June 22 and 23, the funds sold a total of 7,718 shares at prices around $9 per share. After these trades, entities advised by AWM indirectly held 4,879,773 shares of common stock, spread across several Special Situations funds. AWM is described as having sole voting and investment power over these fund holdings, while formally disclaiming beneficial ownership except to the extent of its pecuniary interest.
908 Devices Inc. director Brandi C. Vann received new equity awards consisting of stock options and restricted stock units. The filing shows a grant of options to buy 6,209 shares of Common Stock at an exercise price of $8.22 per share, expiring on June 10, 2036. These options vest in substantially equal monthly installments over the 12 months following June 11, 2026, contingent on continued service.
Vann also received 13,656 Restricted Stock Units, each representing a contingent right to one share of Common Stock. The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, whichever occurs first, with prorated vesting if service ends earlier. These are compensation-related awards rather than open-market purchases or sales.
908 Devices Inc. director Michele M. Leonhart reported equity compensation transactions involving stock options, restricted stock units (RSUs), and common shares. On June 10, 2026, 14,083 RSUs fully vested and were converted into 14,083 shares of common stock, increasing her direct common stock holdings to 20,568 shares.
On June 11, 2026, she received a grant of 6,209 stock options with an exercise price of $8.22 per share that vest in substantially equal monthly installments over 12 months. She also received 13,656 RSUs that vest in full on June 11, 2027 or the day prior to the 2027 annual stockholders meeting, subject to continued service, with prorated vesting if service ends earlier.
908 Devices Inc. director E. Kevin Hrusovsky reported several equity compensation awards and related share movements. He received a stock option grant for 6,209 shares of Common Stock at an exercise price of $8.22 per share, vesting in substantially equal monthly installments over 12 months following June 11, 2026, and expiring on June 10, 2036.
He was also granted 13,656 Restricted Stock Units (RSUs), each representing one share of Common Stock, which become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, subject to continued service and prorated vesting on earlier termination. In addition, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 shares of Common Stock, bringing his direct Common Stock holdings to 165,390 shares. A further 329,675 shares of Common Stock are held indirectly through the E. Kevin Hrusovsky 2012 Irrevocable Trust, for which his spouse and children serve as trustees and over which he may be deemed a beneficial owner.
908 Devices Inc. director Anthony Hunt reported routine equity compensation and a vesting event. He received a stock option for 6,209 shares of Common Stock with an exercise price of $8.22 per share, vesting in substantially equal monthly installments over the 12 months following June 11, 2026, and expiring on June 10, 2036. He was also granted 13,656 Restricted Stock Units (RSUs), which will fully vest on June 11, 2027 or the day prior to the 2027 Annual Meeting of Stockholders, subject to continued service, with prorated vesting upon earlier termination. Separately, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 shares of Common Stock, increasing his direct Common Stock holdings to 44,168 shares.
908 Devices Inc. director ELOI FENEL M reported equity awards and an option exercise-related share delivery. On June 10, 2026, 14,083 Restricted Stock Units vested and converted into 14,083 shares of Common Stock, bringing direct holdings to 40,897 shares.
On June 11, 2026, the director received a grant of 6,209 stock options with an exercise price of $8.22 per share, expiring on June 10, 2036, which vest in substantially equal monthly installments over the 12 months following June 11, 2026. The director was also granted 13,656 Restricted Stock Units that vest in full on June 11, 2027 or the day prior to the 2027 annual stockholders’ meeting, with prorated vesting if service ends earlier.
908 Devices Inc. director Keith Crandell reported equity compensation activity and a derivative exercise. On June 11, 2026, he received a stock option grant for 6,209 shares of Common Stock at an exercise price of $8.22 per share, vesting in equal monthly installments over 12 months, and a grant of 13,656 Restricted Stock Units (RSUs) that vest in full on June 11, 2027 or the day prior to the 2027 annual meeting, subject to continued service and prorating on earlier termination. On June 10, 2026, 14,083 RSUs became fully vested and were converted into 14,083 shares of Common Stock, leaving 39,374 shares of Common Stock held directly after the transaction. An entity, ARCH Venture Fund VII, L.P., associated through layered general partners with Crandell as a managing director, holds 5,725,045 shares of Common Stock indirectly; he may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of his pecuniary interest.
908 Devices Inc. director Mark Spoto reported multiple equity compensation transactions. He received a grant of 6,209 stock options to buy Common Stock at an exercise price of $8.22 per share, which vest in substantially equal monthly installments over the 12 months following June 11, 2026 and expire on June 10, 2036.
He also received 13,656 Restricted Stock Units, each representing a contingent right to one share of Common Stock, that become fully vested on June 11, 2027 or the day before the 2027 annual stockholder meeting, with prorated vesting if his service ends earlier. Separately, 14,083 RSUs became fully vested on June 10, 2026 and were converted into 14,083 Common Stock shares, bringing his direct Common Stock holdings to 89,346 shares.
In addition, 3,599 Common Stock shares are held indirectly through Razor's Edge Ventures, LLC, where he is a managing member and may be deemed a beneficial owner, though he disclaims beneficial ownership beyond his pecuniary interest.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 100 shares of Common Stock at $9.00 per share on June 4, 2026. After this transaction, he directly holds 875,459 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
AWM Investment Company, Inc., as investment adviser to several funds, reported open-market sales of 908 Devices Inc. common stock held indirectly through limited partnerships. The transactions covered 39,782 shares at a weighted-average price of $8.9703 on June 4, 2026 and 2,500 shares at $8.95 on June 2, 2026. After these sales, entities advised by AWM reported holding 4,887,491 shares indirectly. AWM and its principals disclaim beneficial ownership of these shares except to the extent of their pecuniary interest.
908 Devices Inc. director Christopher D. Brown sold shares of company stock. On this Form 4, he reported an open-market sale of 20,000 shares of common stock at a weighted average price of $8.73 per share. After the transaction, he directly holds 875,559 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc., reported open-market sales totaling 186,942 shares of common stock through a limited partnership on May 27–28, 2026. Sale prices ranged from about $8.25 to $8.66 per share, leaving 4,929,773 shares indirectly held afterward. AWM reports these holdings as investment adviser to several funds and disclaims beneficial ownership beyond its pecuniary interest.
908 Devices Inc. Chief Financial Officer Joseph H. Griffith IV sold 6,940 shares of Common Stock in an open-market transaction at a price of $9.03 per share on May 28, 2026.
After this sale, he continues to hold 132,956 shares directly. The filing notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the sale was scheduled in advance rather than timed discretionarily.
908 Devices Inc. director Christopher D. Brown sold 30,000 shares of Common Stock in an open-market transaction at $9.00 per share. After the sale on May 28, 2026, he directly held 895,559 shares of the company’s stock. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
AWM Investment Company, Inc., a 10% owner of 908 Devices Inc., reported an indirect open-market sale of 5,000 shares of Common Stock at a weighted average price of $8.2514 per share on May 11, 2026.
The shares are held through a limited partnership, and AWM reports indirect ownership. After this transaction, entities advised by AWM collectively held 5,116,715 shares of 908 Devices Common Stock. AWM and its principals disclaim beneficial ownership beyond their pecuniary interest.
908 Devices Inc. senior vice president of sales and product marketing John Kenneweg sold 18,255 shares of Common Stock in an open-market transaction on May 8, 2026 at a weighted average price of $8.11 per share. The sales occurred at prices ranging from $7.99 to $8.20. After these transactions, he directly owns 57,784 shares of 908 Devices Common Stock.
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc., reported indirect open-market sales of the company’s common stock through a limited partnership. Across four transactions on May 6–8, AWM-related funds sold a total of 78,209 shares at prices around $8 per share.
Individual trades included 5,000 shares at $8.00, 57,365 shares at $8.0564, 12,819 shares at $8.2042, and 3,025 shares at $8.20. After these sales, AWM, as investment adviser to several funds, reports indirect ownership of 5,121,715 shares and disclaims beneficial ownership except for its pecuniary interest.
908 Devices Inc. director Christopher D. Brown sold shares in a planned transaction. On May 6, 2026, he completed an open-market sale of 20,000 shares of common stock at a weighted average price of $7.23 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
After this sale, Brown directly holds 925,559 shares of 908 Devices common stock. The shares were sold in multiple trades at prices ranging from $7.00 to $7.49 per share.
908 Devices Inc. SVP John Kenneweg reported a routine equity compensation event involving vested performance stock units (PSUs) and a related tax sale. On May 1, 2026, 26,042 PSUs vested and were converted into 26,042 shares of Common Stock. To cover tax withholding obligations from this vesting, 7,787 shares of Common Stock were sold in an open-market “sell to cover” transaction at $6.83 per share, a sale mandated by the company’s election and described as non-discretionary for the insider. Following these transactions, Kenneweg directly holds 76,039 shares of Common Stock, and all of the reported PSUs have been fully settled.
Kenneweg John reported acquisition or exercise transactions in this Form 4 filing.
908 Devices Inc. reported that SVP of Sales & Product Marketing John Kenneweg received a grant of 26,042 Performance Stock Units. Each unit represents a contingent right to receive one share of Common Stock with a par value of $0.001 when it vests.
The compensation committee certified achievement of the required performance metrics and goals on April 28, 2026, and the PSUs are scheduled to vest on May 1, 2026 in accordance with their terms. The PSUs have no expiration date, and this filing reflects a compensation-related equity award rather than an open-market trade.
908 Devices Inc. reported equity compensation grants to Chief Business & Strategy Officer Otitoju Kolawole A. on April 21, 2026. He received 110,193 restricted stock units, each representing one share of common stock, vesting in three substantially equal annual installments on the anniversaries following May 1, 2026, subject to continued service.
He was also granted a stock option for 146,789 shares of common stock at an exercise price of $7.26 per share, expiring on April 20, 2036. One-third of these option shares vest on May 1, 2027, with the remaining two-thirds vesting in substantially equal monthly installments over the following 24 months, contingent on continued service. These are compensation awards rather than open-market purchases or sales.
908 Devices Inc. senior vice president Kevin J. McCallion exercised stock options for 2,693 shares of common stock at $1.05 per share and sold the same 2,693 shares at a weighted average price of $7.01 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was pre‑scheduled. Following the transactions, he directly holds 44,925 shares of common stock, and the underlying option grant is now fully exercised.
908 Devices Inc. senior vice president Kevin J. McCallion exercised employee stock options and immediately sold the resulting shares in planned trades. He exercised options for 24,000 shares of common stock at $1.05 per share, then sold 24,000 shares in open-market transactions at weighted-average prices around $7.04 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was scheduled in advance. After these transactions, McCallion directly holds 44,925 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported open-market sales of 40,000 shares of Common Stock. The transactions occurred over three days at prices around $7 per share, under a Rule 10b5-1 trading plan adopted on November 24, 2025.
Brown sold 15,030 shares at a weighted average price of $7.05 on April 8, 7,392 shares at $7.04 on April 9, and 17,578 shares at $7.07 on April 10. After these sales, he continues to hold 945,559 shares directly, indicating he retains a substantial equity position in the company.
908 Devices Inc. senior vice president of Products and Production, Kevin J. McCallion, reported small insider transactions in company stock. On March 2, 2026, he exercised a stock option for 7 shares at $1.05 per share and received fully vested, immediately exercisable shares.
He then sold 7 shares of common stock at $7.00 per share in an open-market transaction made under a Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly held 26,686 option shares and 44,925 common shares.
908 Devices Inc. senior vice president Kevin J. McCallion reported an open-market sale of 7 shares of common stock at $7.00 per share on March 2, 2026. After this trade, he directly holds 44,918 common shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025.
908 Devices Inc. director Christopher D. Brown reported the settlement of three batches of restricted stock units (RSUs) into Common Stock on February 1, 2026. RSUs covering 5,027, 7,418, and 10,992 shares converted into the same number of Common shares at an exercise price of $0 per share.
Following these vesting events, Brown directly beneficially owns 985,559 shares of Common Stock and 21,982 RSUs. The RSU awards vest in four substantially equal annual installments on anniversary dates following February 1, 2022, February 1, 2023, and February 1, 2024, subject to his continued service.
908 Devices Inc. President and CEO Kevin J. Knopp reported equity compensation activity and a tax-related share sale. On February 1, 2026, several Restricted Stock Units vested and were settled for 11,255, 13,449, 17,007, and 66,288 shares of common stock, increasing his direct holdings to 830,732 shares.
On February 2, 2026, Knopp sold 34,764 shares of common stock at a weighted average price of $6.18 solely to cover tax withholding from the RSU vesting, leaving 795,968 shares held directly. He also received 205,978 new RSUs and a stock option for 90,043 shares at a $6.19 exercise price, which begin vesting on February 1, 2027. Separately, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law serves as trustee with sole voting and dispositive control.
908 Devices Inc. Chief Financial Officer Joseph H. Griffith IV reported a mix of equity grants, vesting and a tax-related sale. On February 1, 2026, several tranches of RSUs vested and settled into 5,102, 10,306, 11,260 and 43,473 shares of common stock. On February 2, 2026, he received 121,164 new RSUs and a stock option for 52,967 shares with a $6.19 exercise price. That same day, he sold 23,175 shares at a weighted average of $6.18 solely to cover tax withholding triggered by the RSU vesting, under a required “sell to cover” arrangement. After these transactions, he directly held 139,896 shares of common stock.
Director Mark Spoto of 908 Devices Inc. reported family-related movements of common stock. On 10/14/2025, 928 shares were acquired at $0 and held indirectly through his spouse. On 12/30/2025, 928 shares were reported as a gift from his spouse, leaving 928 shares no longer held indirectly and 928 shares counted as directly owned, with a total of 75,263 common shares shown as directly held afterward. The filing also shows 3,599 common shares held indirectly through Razor's Edge Ventures, LLC, an entity where Spoto is a managing member and for which he disclaims beneficial ownership beyond his pecuniary interest.
908 Devices Inc. Chief Financial Officer Joseph H. Griffith IV reported planned stock sales under a Rule 10b5-1 trading plan. The filings show sales on 10/02/2025 and 10/03/2025 totaling 5,000 shares (708 shares and 4,292 shares) at weighted-average prices near $9.04 and $9.05, respectively. After these transactions the reporting person beneficially owned 92,930 shares. The footnotes state the sales were executed under the 10b5-1 plan and disclose price ranges for the multiple transactions.
908 Devices Inc. insider transaction summary Joseph H. Griffith IV, the company’s Chief Financial Officer, reported the sale of 5,000 shares of 908 Devices Inc. (ticker: MASS) on 09/19/2025 at a weighted-average price of $7.0677 per share under a pre-established Rule 10b5-1 trading plan. After the sale, the reporting person beneficially owned 97,930 shares. The filing includes an offer to provide detailed breakdowns of the separate sale prices within the $7.03–$7.14 range and is signed by an attorney-in-fact on behalf of the reporting person.